Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Dexcom Inc (NASDAQ:DXCM) EVP, Chief Legal Officer Michael Jon Brown, sold 500 shares of the company’s common stock on June 16, 2025, at a price of $82.80, for a total transaction value of $41,400. While this insider sale occurs, InvestingPro data shows management has been actively buying back shares, and the company maintains a "GREAT" financial health score.
Following the transaction, Brown directly owns 95,102 shares of Dexcom, which includes 86,490 unvested restricted stock units.
The sale was executed under a pre-arranged 10b5-1 trading plan adopted by Brown on February 21, 2025.
In other recent news, DexCom ’s financial performance and market potential have attracted significant attention from multiple analyst firms. Canaccord Genuity increased its price target for DexCom to $106, citing strong U.S. sales performance and potential growth in the Type 2 non-insulin market. The firm noted that DexCom’s first-quarter results exceeded revenue expectations domestically, despite falling short internationally. Truist Securities initiated coverage with a Buy rating and a $102 price target, highlighting the company’s leadership in continuous glucose monitoring and potential for revenue growth driven by reimbursement expansions and technology integrations. Piper Sandler maintained an Overweight rating with a $100 target, indicating a favorable outlook based on a survey of diabetes educators that suggests DexCom will gain market share among basal insulin users. Goldman Sachs also began coverage with a Buy rating and a $104 target, emphasizing DexCom’s innovative technology and untapped consumer adoption potential. RBC Capital Markets reiterated an Outperform rating and a $100 target, pointing to DexCom’s expanding U.S. Pharmacy Benefit Manager coverage and increasing profitability. These recent developments underscore the confidence analysts have in DexCom’s growth trajectory and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.